Overview

Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

- Evaluation of the non inferiority of Meclin (meclizine) versus Dramin (Dimenhydrinate) to treat the symptoms of acute vertigo from peripheral origin after up to 4 weeks of treatment; - Evaluation of impact on quality of life in vertigo; - Compare the intensity of daytime sleepiness in the two treatment groups; - Compare the efficacy of drugs in relieving each of the 10 symptoms that make up the VS; - Compare the duration of treatment in both treatment groups; - Compare Adehence; - Compare the level of satisfaction from each group from the investigators and the subjects; - Adverse events;

Phase:

Phase 3

Details

Lead Sponsor:

Apsen Farmaceutica S.A.

Treatments:

Dimenhydrinate
Meclizine